BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31580832)

  • 1. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes.
    Samson JM; Ravindran Menon D; Smith DE; Baird E; Kitano T; Gao D; Tan AC; Fujita M
    Chem Biol Interact; 2019 Dec; 314():108822. PubMed ID: 31580832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
    Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A
    BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells.
    Croker AK; Rodriguez-Torres M; Xia Y; Pardhan S; Leong HS; Lewis JD; Allan AL
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.
    Gorodetska I; Offermann A; Püschel J; Lukiyanchuk V; Gaete D; Kurzyukova A; Freytag V; Haider MT; Fjeldbo CS; Di Gaetano S; Schwarz FM; Patil S; Borkowetz A; Erb HHH; Baniahmad A; Mircetic J; Lyng H; Löck S; Linge A; Lange T; Knopf F; Wielockx B; Krause M; Perner S; Dubrovska A
    Theranostics; 2024; 14(2):714-737. PubMed ID: 38169509
    [No Abstract]   [Full Text] [Related]  

  • 5. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
    Luo Y; Dallaglio K; Chen Y; Robinson WA; Robinson SE; McCarter MD; Wang J; Gonzalez R; Thompson DC; Norris DA; Roop DR; Vasiliou V; Fujita M
    Stem Cells; 2012 Oct; 30(10):2100-13. PubMed ID: 22887839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling.
    Ciccone V; Simonis V; Del Gaudio C; Cucini C; Ziche M; Morbidelli L; Donnini S
    Biochem Pharmacol; 2024 Jun; 224():116252. PubMed ID: 38701866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
    You Q; Guo H; Xu D
    Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and kinetic features of aldehyde dehydrogenase 1A (ALDH1A) subfamily members, cancer stem cell markers active in retinoic acid biosynthesis.
    Pequerul R; Vera J; Giménez-Dejoz J; Crespo I; Coines J; Porté S; Rovira C; Parés X; Farrés J
    Arch Biochem Biophys; 2020 Mar; 681():108256. PubMed ID: 31923393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.
    Marcato P; Dean CA; Liu RZ; Coyle KM; Bydoun M; Wallace M; Clements D; Turner C; Mathenge EG; Gujar SA; Giacomantonio CA; Mackey JR; Godbout R; Lee PW
    Mol Oncol; 2015 Jan; 9(1):17-31. PubMed ID: 25106087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer.
    Liu Y; Baglia M; Zheng Y; Blot W; Bao PP; Cai H; Nechuta S; Zheng W; Cai Q; Shu XO
    Oncotarget; 2015 Dec; 6(38):41360-9. PubMed ID: 26462023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer.
    Rebollido-Rios R; Venton G; Sánchez-Redondo S; Iglesias I Felip C; Fournet G; González E; Romero Fernández W; Borroto Escuela DO; Di Stefano B; Penarroche-Díaz R; Martin G; Ceylan I; Costello R; Perez-Alea M
    Oncogene; 2020 Mar; 39(13):2756-2771. PubMed ID: 32015486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells.
    Jiménez R; Pequerul R; Amor A; Lorenzo J; Metwally K; Avilés FX; Parés X; Farrés J
    Chem Biol Interact; 2019 Jun; 306():123-130. PubMed ID: 30958995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct expression patterns and roles of aldehyde dehydrogenases in normal oral mucosa keratinocytes: differential inhibitory effects of a pharmacological inhibitor and RNAi-mediated knockdown on cellular phenotype and epithelial morphology.
    Kato H; Izumi K; Saito T; Ohnuki H; Terada M; Kawano Y; Nozawa-Inoue K; Saito C; Maeda T
    Histochem Cell Biol; 2013 Jun; 139(6):847-62. PubMed ID: 23250514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
    Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW
    Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
    Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
    Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.
    Li G; Li Y; Liu X; Wang Z; Zhang C; Wu F; Jiang H; Zhang W; Bao Z; Wang Y; Cai J; Zhao L; Kahlert UD; Jiang T; Zhang W
    Cell Death Dis; 2018 Dec; 9(12):1190. PubMed ID: 30538217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldehyde dehydrogenase 1A1 and 1A3 isoforms - mechanism of activation and regulation in cancer.
    Poturnajova M; Kozovska Z; Matuskova M
    Cell Signal; 2021 Nov; 87():110120. PubMed ID: 34428540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion.
    Zhang W; Liu Y; Hu H; Huang H; Bao Z; Yang P; Wang Y; You G; Yan W; Jiang T; Wang J; Zhang W
    PLoS One; 2015; 10(11):e0142856. PubMed ID: 26575197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.